Fidelity Investments’s AGF US Market Neutral Anti-Beta Fund BTAL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$21.7M Hold
1,944,444
﹤0.01% 1855
2026
Q1
$27.1M Hold
1,944,444
﹤0.01% 1663
2025
Q4
$28M Hold
1,944,444
﹤0.01% 1658
2025
Q3
$31M Sell
1,944,444
-345
-0% -$5.68K ﹤0.01% 1618
2025
Q2
$34.4M Buy
1,944,789
+1,944,184
+321,353% +$37.9M ﹤0.01% 1525
2025
Q1
$12.6K Buy
605
+367
+154% +$6.96K ﹤0.01% 4411
2024
Q4
$4.4K Buy
+238
New +$4.58K ﹤0.01% 4691
2024
Q3
Sell
-1,070
Closed -$21K 5511
2024
Q2
$21K Buy
+1,070
New +$20.3K ﹤0.01% 4046
2024
Q1
Sell
-1
Closed -$17 5386
2023
Q4
$17 Buy
+1
New +$20 ﹤0.01% 5239
2023
Q3
Sell
-102
Closed -$1.91K 5294
2023
Q2
$1.91K Buy
102
+72
+240% +$1.45K ﹤0.01% 4599
2023
Q1
$612 Buy
+30
New +$604 ﹤0.01% 4773
2020
Q4
Sell
-1,461
Closed -$34K 3840
2020
Q3
$34K Buy
+1,461
New +$35K ﹤0.01% 2955

Other funds holding BTAL

Fidelity Investments's BTAL Position: Q2 2026 in Review

Fidelity Investments held its AGF US Market Neutral Anti-Beta Fund (BTAL) position steady in Q2 2026 at 1,944,444 shares worth $21.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1855.

Fidelity Investments first reported a position in BTAL in Q3 2020 and has held it in 12 quarters since. The position peaked at $34.4M in Q2 2025. 93 funds tracked by Wall St. Rank hold BTAL as of Q2 2026.

  • Fidelity Investments held 1,944,444 shares of AGF US Market Neutral Anti-Beta Fund worth $21.7M as of Q2 2026.
  • Fidelity Investments left its AGF US Market Neutral Anti-Beta Fund share count unchanged in Q2 2026.
  • AGF US Market Neutral Anti-Beta Fund made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #1855 holding.
  • Fidelity Investments first reported a position in AGF US Market Neutral Anti-Beta Fund in Q3 2020 and has held it in 12 quarters since.
  • Fidelity Investments's AGF US Market Neutral Anti-Beta Fund position peaked at $34.4M in Q2 2025.
  • 93 funds tracked by Wall St. Rank held AGF US Market Neutral Anti-Beta Fund as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.